Xeno Transplants Corporation (XENO)
Xeno Transplants Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Brookline, MA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $4,036. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of 0.0%. Its beta of -0.28 implies it has historically moved less than the broad market.
Xeno Transplants Corporation functions as a biotechnology firm dedicated to research and development. Leveraging a specific licensing agreement with Massachusetts General Hospital, the company aims to innovate, produce, commercialize, and implement products and methodologies for public application in the field of xenotransplantation. The primary objective of this xenotransplantation research is to alleviate the critical scarcity of human cells, tissues, and organs required for medical transplants. This is achieved by pioneering techniques that enable the transfer of biological components—such as cells, tissues, and organs—from non-human species, including pigs, into human recipients. Established in 2004, Xeno Transplants Corporation maintains its headquarters in Brookline, Massachusetts.
Xeno Transplants Corporation is most often compared with the following Healthcare names: